In this section
Section highlightHouses into homes This report details findings to emerge from the evaluation during the first six months of delivery (April to September 2012).
Written Statement - The Draft Control of Dogs (Wales) Bill »We are committed to ensuring that out-of-control and dangerous dogs are dealt with effectively.Learn more »
Consultation on proposals for ground-breaking legislation to reform arrangements for renting homes
Minister for Housing and Regeneration Carl Sargeant has launched a White Paper for consultation on the Welsh Government’s legislative proposals to improve arrangements for renting homes.
- Cardiff Airport key to Wales’ position in global market – First Minister
- Culture Minister pledges support to Welsh broadcast industry
- Consultation on proposals for ground-breaking legislation to reform arrangements for renting homes
In this section
- Business and economy
- Children and young people
- Culture and sport
- Education and skills
- Environment and countryside
- Equality and diversity
- Health and social care
- Housing and community
- Improving public services
In this section
Section highlightAccess to information
The Welsh Government has followed the principles of openness in government for many years. Find out how you can make a freedom of information request or see requests that have already been made.
National minimum standards for regulated child care »These standards determine whether child minding and day care settings are providing adequate care for children under the age of 8.Learn more »
- Higher Education (Wales) Bill: Technical consultation
- Renting Homes White Paper
- Continuity and Change - Refreshing the Relationship between Welsh Government and the Third Sector in Wales
- Development of a national standards and outcomes framework for Children and Young People's advocacy services in Wales
- Strategic Environmental Assessment: Environmental Report, Rural Development Plan for Wales 2014-2020
- The draft School Governors’ Annual Reports (Wales) (Amendment) Regulations 2013
Featured consultation »Implementing the Domestic Fire Safety (Wales) Measure 2011
27 days left
In this section
Section highlightFurther and Higher Education (Governance and Information) (Wales) Bill 2013
Removes a number of technical restrictions and controls on colleges without changing the principal powers of colleges to provide further, higher and secondary education.
Legislative programme 2012 - 2013 »
Addressing the Assembly in the Senedd today, the First Minister, Carwyn Jones, detailed the eight bills in the Welsh Government’s 5-year Legislative Programme that will be brought forward during the second year of the Welsh Assembly.Learn more »
Section highlightCommunity Infrastructure Levy
Local authorities can charge a Community Infrastructure Levy on new developments to support the infrastructure needed.
2nd Supplementary Budget 2012-13 »
Proposes a number of changes to the 1st Supplementary Budget for 2012-13, which was published on 26 June 2012.Learn more »
Disease Modifying Therapies for Multiple Sclerosis
The issue of prescribing Disease Modifying Therapies (DMTs) to patients with relapsing-remitting and secondary progressive Multiple Sclerosis (MS) was recently raised with members of the Health and Social Services Committee. My officials and I are aware that at present there are difficulties providing DMTs to newly diagnosed MS patients and we are taking action to help resolve this situation.
MS is a demyelinating disease of the central nervous system. It is the most frequent cause of neurological disability in young adults, and it is characterised by chronic relapse and disease progression. There is currently no effective cure for MS. A group of drugs (Beta Interferon and Glatiramer Acetate) known as the Disease Modifying Therapies are used to help reduce the number and severity of relapses and slow disease progression.
In 2002 the National Institute for Clinical Excellence (NICE) concluded that on the balance of clinical and cost effectiveness, neither Beta Interferon nor Glatriamer Acetate could be recommended for the treatment of Multiple Sclerosis in the NHS in England and Wales. The MS Risk Sharing Scheme was however established in 2002 following an invitation by NICE for the Department of Health, the Welsh Assembly Government and manufacturers to consider what actions could be taken to enable DMTs for MS to be provided in a more cost effective way and appraised over a 10-year period.
The Assembly Government has invested in the infrastructure for the MS Risk Sharing Scheme in Wales since 2002 and has put arrangements in place to support the provision of DMTs to patients with MS who meet the eligibility criteria established by the Association of British Neurologists (ABN).
My officials and I are aware of the increasing demands for DMTs for MS across Wales and during the financial year 2005-6, Health Commission Wales (HCW) invested £2.5 million in DMTs and the infrastructure necessary for the care and monitoring of MS patients using these drugs.
Despite this investment the demands for DMTs have continued to rise and I am aware that a number of patients have been unable to commence therapy due to pressures on current resources at the three prescribing centres set up to treat Welsh MS patients. In light of this, financial allocations for 2006/07 will be considered within the overall allocation to HCW and in the commissioning plans currently being developed.
We are taking a number of steps to help resolve these issues while continuing to support the provision of DMTs to patients that have commenced treatment under the guidance of the MS Risk Sharing. My officials are: -
- Making plans to undertake a review of current practice in Wales to assess the treatment of MS patients against the criteria of the ABN.
- Addressing the epidemiology and prevalence of MS to help gain a greater understanding of future trends to support key commissioning decision
- Reviewing the latest evidence and research findings
- Liaising with the other UK health departments to discuss a joint review of the MS Risk Sharing Scheme to help ensure an equitable, appropriate and sustainable approach for the provision of DMTs in the longer term.
We will also be assessing the outcomes of the interim report of the national MS Risk Sharing Scheme, due in autumn 2006, to inform the way forward for the future management of services for MS.